---
type: earnings-call
company: "Doximity"
ticker: DOCS
quarter: Q3
fiscal_year: 2024
source: "Yahoo Finance"
source_url: "https://finance.yahoo.com/news/doximity-inc-nyse-docs-q3-152809558.html"
---

## Summary

Doximity reported strong Q3 FY24 results, beating revenue and EBITDA guidance. They raised full-year revenue and EBITDA guidance due to stronger-than-expected upsells. Key growth drivers include increased engagement on their platform, adoption of their EHR-integrated workflow tools, and success in selling newer modules.

## Financial Highlights

[
  {
    "metric": "Revenue",
    "value": "135.3 million",
    "yoy_change": "17%"
  },
  {
    "metric": "Adjusted EBITDA",
    "value": "73.3 million",
    "yoy_change": null
  },
  {
    "metric": "Adjusted EBITDA Margin",
    "value": "54%",
    "yoy_change": null
  },
  {
    "metric": "Net Revenue Retention Rate",
    "value": "115%",
    "yoy_change": null
  },
  {
    "metric": "Free Cash Flow",
    "value": "48.7 million",
    "yoy_change": "3%"
  }
]

## Guidance

{'Q4_revenue': '115.9 million to 116.9 million', 'Q4_adjusted_EBITDA': '50.5 million to 51.5 million', 'FY24_revenue': '473.3 million to 474.3 million', 'FY24_adjusted_EBITDA': '224.5 million to 225.5 million'}

## Strategic Initiatives

['Focus on AI-fueled growth, leveraging HIPAA-compliant GPT product.', 'Expansion of the client portal to unlock smaller clients.', 'Emphasis on point-of-care and other new modules that grew >100% YoY.', 'Continued growth with existing customers. Top 20 customer NRR at 122%', 'Increase brands spending at least $1M to 75 brands.', 'Share repurchase program; decreased fully diluted shares by roughly 6%.']

## Risk Factors

['Q4 revenue outlook reflects growth more indicative of program launch timing than underlying sales growth.']

---

## Full Transcript

Doximity, Inc. (NYSE:DOCS) Q3 2024 Earnings Call Transcript February 8, 2024

Doximity, Inc. beats earnings expectations. Reported EPS is $0.29, expectations were $0.24. Doximity, Inc. isnâ€™t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator:Thank you for standing by. My name is Aaron, and I'll be your conference operator for today. At this time, I would like to welcome everyone to the Doximity Fiscal Third Quarter 2024 Earnings Call. [Operator Instructions] I would now like to turn the call over to Perry Gold, Vice President of Investor Relations. Please go ahead.

Perry Gold:Thank you, operator. Hello, and welcome to Doximity's fiscal 2024 third quarter earnings call. With me on the call today are Jeff Tangney, Co-Founder and CEO of Doximity; Dr. Nate Gross, Co-Founder and CSO; and Anna Bryson, CFO. A complete disclosure of our results can be found in our press release issued earlier today as well as in our related Form 8-K, all of which are available on our website at investors.doximity.com. Starting this quarter, we published our prepared remarks in conjunction with the press release and you can find them on the IR website. As a reminder, today's call is being recorded and a replay will be available on our website. As part of our comments today, we will be making forward-looking statements.

These statements are based on management's current views, expectations and assumptions and are subject to various risks and uncertainties. Actual results may differ materially, and we disclaim any obligation to update any forward-looking statements or outlook. Please refer to the Risk Factors in our Annual Report on Form 10-K and any subsequent Form 10-Qs, and our other reports and filings with the SEC that may be filed from time to time, including our upcoming filing on Form 10-Q. Our forward-looking statements are based on assumptions that we believe to be reasonable as of today's date, February 8, 2024. Of note, it is Doximity's policy to neither reiterate nor adjust the financial guidance provided on today's call, unless it is also done through a public disclosure, such as a press release or through the filing of a Form 8-K.

Today we will discuss certain non-GAAP metrics that we believe aid in the understanding of our financial results. A historical reconciliation to comparable GAAP metrics can be found in today's earnings release. Finally, during the call, we may offer incremental metrics to provide greater insights into the dynamics of our business. These details may be one-time in nature and we may or may not provide updates on those metrics in the future. I would now like to turn the call over to our CEO and Co-Founder, Jeff Tangney. Jeff?

Jeffrey Tangney:Thanks, Perry, and thank you, everyone, for joining our third quarter earnings call. We have three updates today: our financials, product highlights and a new leadership hire. First, our top line. I'm pleased to report that we delivered $135 million in revenue for the third quarter of our fiscal 2024, a 6% beat versus the high end of our guidance and 17% growth year-on-year. Our bottom line was also strong in Q3 with an adjusted EBITDA margin of 54% or $73 million, which was 18% above the high end of our guidance. Looking ahead, we're raising our fiscal 2024 annual revenue guidance midpoint by $8 million or 2%. We're also raising our EBITDA guidance midpoint by 6% to $225 million or a 47% margin. So that's our Q3 financial highlights, a 6% beat, 2% raise and a 54% EBITDA margin.

Okay. Turning now to our physician network. Our Q3 engagement reached a new high watermark. Our unique active users on a quarterly, monthly, weekly and daily basis were all up double-digit percentages year-on-year. As with last quarter, our daily users grew the most, underscoring how much our EHR integrated workflow tools continue to gain share and daily use among doctors. On that front, we're thrilled to announce that for the third year in a row, Doximity has been ranked the number 1 best-in-class telehealth video platform by health system CIOs and their staff, beating out Microsoft Teams, Zoom and many others. This positive word of mouth, allowed us to add several major new hospital clients in Q3. Go-lives at these hospital systems contributed to a record 560,000 unique prescribers using our workflow software in Q3.

We now count 17 of the top 22 U.S. hospitals as enterprise software clients and all of them as marketing clients. Alongside our workflow products, our personalized physician newsfeeds also hit new highs in Q3 with both record reach and usage. We're proud to be the newsfeed of medicine, the place where doctors go when they have a few minutes to check in on the latest news in their field. Our next phase of growth, we believe, will be AI fueled. Our HIPAA-compliant GPT product has organically grown to thousands of users each day, and we love all the ways it's already helping doctors cut the skat and reduce their administrative load. To that end, we're excited to convene our 12th Annual Docs Tech Summit in San Francisco next month. It will be 150 of our nation's top digital doctors, rolling up their sleeves alongside our engineers designing software to save time and improve patient care.

We also can't wait for our Pharmaceutical Client Summit in early May to unveil our new client portal. We've opened up the portal now to about 10% of our brand partners, and the early reviews have been great. Our portals AI brainstorm bot is a hit, but it's our real-time engagement reports and seamless prescription sales data that keeps them coming back. As one pharma brand manager put it, "This is great. I can tweak it, run it, tweak it again until we get the right content to the right doctors." The portal's transparency and ease of use also gets high marks. Another top client told us, "I love that I can see my results anytime, anywhere without someone else touching it first." To be clear, we don't yet allow clients to actually purchase on the portal.

But when we do, we think it could unlock the longer tail of small and midsized clients that we're not able to reach today. It will also make it easier for us to launch new modules that leverage our workflow engagement. As our CFO, Anna, will share in a moment, our new point of care and other modules grew over 100% year-on-year last quarter. So we believe we're still in the early innings of monetizing our workflow platform. On that note, I'm pleased to announce the addition of Lisa Greenbaum as our new Chief Commercial Officer. Lisa joins us from Google, where she was Verily's Chief Commercial Officer. Prior to that, she spent 15 years scaling and leading Medscape's go-to-market as their Senior Vice President and General Manager. Lisa's husband is a pediatrician and a long-time Doximity user.

So while she's only been here a month, it feels like she's known us for years. The team and I are excited to have her on board. We know our clients will appreciate Lisa's deep relationships and unique insights from being both a successful tech and healthcare executive at market-leading firms. Okay. I'd like to end by thanking my Doximity teammates who continue to work incredibly hard to realize our mission. I personally have never been more excited or more proud about what we're building together. And with that, I'll hand it over to our CFO, Anna Bryson, to discuss our financials and guidance. Anna?

Anna Bryson:Thanks, Jeff, and thanks to everyone on the call today. Third quarter revenue grew to $135.3 million, up 17% year-over-year and exceeding the high end of our guidance range. Similar to prior quarters, our existing customers continued to lead our growth. We finished the quarter with a net revenue retention rate of 115% on a trailing 12-month basis. For our top 20 customers, net revenue retention was higher at 122%. So our biggest, most sophisticated customers remain our fastest growing. We ended the quarter with 289 customers contributing at least $100,000 each in subscription-based revenue on a trailing 12-month basis. This is a 2% increase from the 282 customers we had in this cohort a year ago. And these customers accounted for 89% of our total revenue.

Turning to our profitability. Non-GAAP gross margin in the third-quarter was 93% versus 91% in the prior year period. Adjusted EBITDA for the third quarter was $73.3 million and adjusted EBITDA margin was 54%, compared to $55.5 million and a 48% margin in the prior year period. These represent new highs for non-GAAP gross and adjusted EBITDA margins. This margin strength was driven by our Q3 revenue outperformance, continued optimization of our infrastructure costs and customer support engines, and a strategic application of AI across our R&D and G&A teams. Now turning to our cash flow, balance sheet, and an update on our share repurchase program. We generated free cash flow in the third quarter of $48.7 million compared to $47.5 million in the prior year period, an increase of 3% year-over-year.

As a reminder, we have utilized our NOL's and are now paying cash taxes at a rate of roughly 25% to 30%. We ended the third quarter with $710 million of cash, cash equivalents and marketable securities. During the third quarter, we repurchased 3.2 million shares at an average price of $22.8, representing $71.7 million. Fiscal year-to-date, we have repurchased $262 million worth of shares at an average price of $22.89. These share repurchase efforts have decreased our fully diluted shares outstanding by roughly 6% from the quarter-ending March 31, 2023 to the quarter ending December 31st, 2023. We still have over $60 million of our most recent share repurchase authorization remaining. Share repurchases have been funded by our free cash flow, and as a reminder, our IPO proceeds remain untouched and available to invest in the business and M&A.

Now I'll turn to a recap of our annual buying season. As a reminder, our December quarter represents our largest sales quarter by a significant amount. This is when our pharma customers sign on for next year's programs, committing the majority of their annual marketing budgets. While we've signed these contracts in Q3, we will primarily recognize revenue over the next 12 months, depending on the timing of program launches. This upfront season, we saw strong growth with our brand partners, particularly amongst the number of brands spending at least $1 million with us. This cohort grew to 75 brands this selling season, an increase of roughly 30% year-over-year. Of these $1 million plus brands, we have three brands that spent at least $10 million each, an increase from the one $10 million plus brand we had last year.

We also saw strength in our modules that often sit outside of traditional marketing budgets, such as Peer-to-Peer, Point-of-Care and Formulary. These modules combined grew by more than 100% year-over-year during our upfront season. We have benefited from our increased focus on selling newer modules on a packaged basis as our customers continue to expand their reach across our entire platform. Now moving on to our outlook, for the fourth fiscal quarter of 2024, we expect revenue in the range of $115.9 million to $116.9 million, representing 5% growth at the midpoint. And we expect adjusted EBITDA in the range of $50.5 million to $51.5 million, representing a 44% adjusted EBITDA margin. For the full fiscal year, we are raising our revenue guidance to the range of $473.3 million to $474.3 million, representing 13% growth at the midpoint.

We are raising our adjusted EBITDA guidance to the range of $224.5 million to $225.5 million, representing a 47% adjusted EBITDA margin. The increased annual outlook reflects stronger-than-expected upsells at calendar year end. As mentioned previously, incremental budgets unlocked later than typical this past year. As those dollars became available, we are encouraged that Doximity remained a top choice for our customers, which is evident in the large step-up in our Q3 revenue. Looking ahead we're excited that our upfront selling season saw deeper investment in our newer modules and the addition of several large new brands. In fiscal Q4, we are focused on getting these new programs live, which in many cases will require new content. As a result, our Q4 revenue outlook reflects growth more indicative of program launch timing than underlying sales growth.

We expect the overall pharma HCP digital market to grow roughly 5% to 7% in calendar year 2024. Based on our upfront selling season, we are confident our pharma business can once again outpace the markets. We are encouraged by the levels of investment our customers are making in Doximity, and are excited by the opportunity to continue delivering innovative solutions, real-time insights and industry-leading ROI. With that. I will turn it over to the operator for questions.

See also10 Best Discount Retailer Stocks to Buyand12 Best Communication Stocks To Buy According To Hedge Funds.

To continue reading the Q&A session, pleaseclick here.
